<DOC>
	<DOC>NCT00247663</DOC>
	<brief_summary>- To investigate the safety of letrozole monotherapy at a dose 1.0 mg/day or fadrozole monotherapy at a dose 2.0mg in Japanese postmenopausal patients with advanced breast cancer which participated in double blind study.</brief_summary>
	<brief_title>Extension Study of 1.0mg Dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>Patients which participated in double blind study Patients with intolerable toxicity. Patients which confirmed progressive disease during double blind study. Patients which have received concurrent anticancer therapy during double blind study.</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Aromatase inhibitor</keyword>
	<keyword>letrozole</keyword>
	<keyword>breast cancer</keyword>
</DOC>